Disputes and regulatory enforcement

Regulatory enforcement and actions against regulators

The highly regulated nature of the life sciences industry gives rise to the potential for a myriad of regulatory enforcement action for breach of the strict rules governing the sector. Similarly, organisations affected by decisions taken by the regulators responsible for regulating the sector may also wish to take action against those decisions. Regulatory enforcement and action against regulators is possible at both at UK and EU level, depending on the nature of the issue in dispute.

Disputes arising out of the EMA’s approach to transparency

Article 15 of the Treaty on the Functioning of the European Union (TFEU) requires EU institutions, bodies, offices, and agencies to conduct their work as openly as possible and extends the public right of access to documents of all the Union institutions, bodies, offices and agencies. This is often referred to as the principle of transparency. Transparency can be pursued by institutions either by granting access to documents or information upon request (reactive disclosure) or by making documents and information publicly available on their own motion, mainly by publishing it on their websites (proactive disclosure). ...

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News
View Life Sciences by content type :

Most recent Disputes and regulatory enforcement content

Practice notes

Introduction to revocation of patentsPatents may be revoked, that is, taken off the register of patents, if it is decided that they are invalid in...
26th Mar
Practice notes

Patent invalidity and revocationThis Practice Note discusses the grounds for patent invalidity and revocation under the Patents Act 1977 (PA 1977),...
26th Mar
Practice notes

Remedies in patent proceedingsIntroduction to patent proceedingsIn England and Wales, disputes concerning patents are heard within the civil...
26th Mar
Practice notes

Legal professional privilege in civil proceedingsThis Practice Note considers legal professional privilege (LPP), which is made up of legal advice...
25th Mar
Practice notes

Arbitration—an introduction to the key features of arbitrationSTOP PRESS: This Practice Note has been updated in light of the new Arbitration Act 2025...
20th Mar
Practice notes

Life sciences cases tracker—UKThis Practice Note is intended to be used to track the progress of UK cases relevant to the life sciences sector.Jump...
20th Mar
Practice notes

Life sciences cases tracker—EUThis Practice Note is intended to be used to track the progress of EU cases relevant to the life sciences sector.Jump...
19th Mar
Practice notes

Privilege—loss or waiver of privilegeThis Practice Note looks at loss of privilege in civil litigation in the context of legal professional privilege...
19th Mar
Practice notes

Privilege—general principlesThis Practice Note considers the general principles, meaning and rationale behind privilege. It identifies the different...
13th Mar
Practice notes

Competition law in the pharmaceutical sectorThis Practice Note covers the application of EU and UK competition law to common practices that take place...
8th Mar
Practice notes

Access to documents and information on medicinal products in the EUIn recent years, we have witnessed a constantly growing interest from all...
8th Mar
Practice notes

Exceptions and defences to patent infringementA ‘patent’ is a document conferring so-called monopoly rights to an inventor. A patent protects new...
8th Mar
Flowcharts

Patent infringement action—flowchartThis Flowchart provides an overview of a UK patent infringement action with links to relevant Practice Notes,...
5th Mar
Practice notes

Comparing arbitration and ADRThis Practice Note compares and contrasts, at a high level and in table form, the key differences between arbitration and...
26th Feb
Practice notes

Cephalon and Teva (Modafinil) (AT.39686) [Archived]CASE HUBNOTE—appeal lodged before the General Court in Case T- 74/21ARCHIVED–this archived case hub...
14th Feb
Practice notes

Unjustified threats of intellectual property right infringementThis Practice Note summarises the application and purpose of the law of unjustified...
14th Feb
Practice notes

The experimental use and Bolar-type exemptions to patent infringementPatent systems are intended to foster innovation, not to impede it. For this...
11th Feb
Practice notes

Illumina/GRAIL (M.10188) [Archived]CASE HUB NOTE—appeals lodged before the General Court in Cases T- 227/21, T- 23/22 and T- 755/21ARCHIVED—this...
10th Feb
Practice notes

Liothyronine tablets (Advanz Pharma) (abuse of dominance) [Archived]CASE HUBARCHIVED—this archived case hub reflects the position at the date of the...
10th Feb
Practice notes

Patent obviousness and common general knowledgeOne of the grounds on which a patent may be revoked is if it does not involve an inventive step, ie it...
10th Feb

Popular documents